In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of the 2021 HF guidelines introduced new key recommendations based on the results of the last years of science. First, two drugs, sodium鈥揼lucose co-transporter-2 (SGLT2) ...
The 2023 update of the European Society of Cardiology (ESC) guidelines recommends (class IA) the administration of sodium-glucose transporter 2 inhibitors (SGLT2i) also for patients with heart failure with preserved ejection fraction (HFpEF) and mildly reduced EF (HFmrEF). Thus, SGLT2i are the...
Mitchell, MD; for the EVALUATE-HF Investigators JAMA Viewpoint Redefining Heart Failure With a Reduced Ejection Fraction Javed Butler, MD, MPH, MBA; Stefan D. Anker, MD; Milton Packer, MD JAMA JAMA Patient Page Patient Information: Heart Failure Jayson R. Baman, MD; Faraz S. Ahmad, MD, ...
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure worldwide, in tandem with ageing of the general population and the increasing prevalences of obesity, diabetes mellitus and hypertension. The clinical syndrome of HFpEF is heterogeneous and ...
Obesity is a major risk factor for heart failure (HF) and highly prevalent in this population, particularly in those with HF with preserved ejection fraction (HFpEF), to the extent that an obesity HFpEF phenotype has been proposed in the literature. However, once HF is developed, an obesity ...
Article Open access 25 January 2024 Introduction Heart failure (HF) is a leading cause of death and morbidity worldwide and is responsible for a large portion of healthcare and disability costs every year1. HF is challenging to treat because it can have various causes, is impacted by a wide...
Basic mechanisms of chronic heart failure are reviewed. A central theme that cuts all the way through this review is that chronic heart failure is a problem of failing complexity, rather than a problem of the failure of a single unit (e.g., cell type) or processes (e.g., contractility)...
今年,在阿姆斯特丹举行的欧洲心脏病学会(ESC)大会举办了9场热线会议,讨论了心血管药物治疗领域一些最受期待且可能改变实践的临床试验。 Heart failure (HF) was the focus of the congress, accounting for nearly a third of the ...
This volume presents a fresh international perspective on current approaches to treating heart failure. An accessible reference for hospital-based specialists, the book provides an update on recent advances in therapeutics and pharmacology, as well as ongoing trials. Four major sections concentrate on a...
Heart failure affects millions of Americans and new diagnosis rates are expected to almost triple over the next 30 years as our population ages. Affective disorders including clinical depression and anxiety are common in patients with congestive heart failure. Furthermore, the presence of these disorde...